#BEGIN_DRUGCARD DB00659

# AHFS_Codes:
Not Available

# ATC_Codes:
N07BB03

# Absorption:
The absolute bioavailability of acamprosate after oral administration is about 11%. The food effect on absorption is not clinically significant and no adjustment of dose is necessary.

# Biotransformation:
Acamprosate does not undergo metabolism.

# Brand_Mixtures:
Not Available

# Brand_Names:
Campral

# CAS_Registry_Number:
77337-76-9

# ChEBI_ID:
51041

# Chemical_Formula:
C5H11NO4S

# Chemical_IUPAC_Name:
3-acetamidopropane-1-sulfonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Acamprosate, also known by the brand name Campral&trade;, is a drug used for treating alcohol dependence. Acamprosate is thought to stabilize the chemical balance in the brain that would otherwise be disrupted by alcoholism, possibly by blocking glutaminergic N-methyl-D-aspartate receptors, while gamma-aminobutyric acid type A receptors are activated. Reports indicate that acamprosate only works with a combination of attending support groups and abstinence from alcohol. Certain serious side effects include allergic reactions, irregular heartbeats, and low or high blood pressure, while less serious side effects include headaches, insomnia, and impotence. Acamprosate should not be taken by people with kidney problems or allergies to the drug.

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Alcohol Deterrents

# Drug_Interactions:
Not Available

# Drug_Reference:
11584875	Mason BJ: Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry. 2001;62 Suppl 20:42-8.
16300039	Williams SH: Medications for treating alcohol dependence. Am Fam Physician. 2005 Nov 1;72(9):1775-80.
16467406	Feeney GF, Connor JP, Young RM, Tucker J, McPherson A: Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy. Alcohol Alcohol. 2006 May-Jun;41(3):321-7. Epub 2006 Feb 8.
16546214	Mason BJ, Goodman AM, Chabac S, Lehert P: Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res. 2006 Aug;40(5):383-93. Epub 2006 Mar 20.
9509257	Tsai G, Coyle JT: The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med. 1998;49:173-84.

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-1.1

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Take without regard to meals.
Taking the product with food reduces its C<sub>max</sub> by 42% and total drug exposure by 23% (not considered significant).

# GenBank_ID:
Not Available

# Generic_Name:
Acamprosate

# HET_ID:
Not Available

# Half_Life:
20 - 33 hours

# InChI_Identifier:
InChI=1S/C5H11NO4S/c1-5(7)6-3-2-4-11(8,9)10/h2-4H2,1H3,(H,6,7)(H,8,9,10)

# InChI_Key:
InChIKey=AFCGFAGUEYAMAO-UHFFFAOYSA-N

# Indication:
For the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D02780

# LIMS_Drug_ID:
659

# Mechanism_Of_Action:
The mechanism of action of acamprosate in maintenance of alcohol abstinence is not completely understood. Chronic alcohol exposure is hypothesized to alter the normal balance between neuronal excitation and inhibition. <i>in vitro</i> and <i>in vivo</i> studies in animals have provided evidence to suggest acamprosate may interact with glutamate and GABA neurotransmitter systems centrally, and has led to the hypothesis that acamprosate restores this balance. It seems to inhibit NMDA receptors while activating GABA receptors.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
181.21

# Molecular_Weight_Mono:
181.040878535

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/cam1691.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA10344

# Pharmacology:
Pharmacodynamic studies have shown that acamprosate calcium reduces alcohol intake in alcohol-dependent animals in a dose-dependent manner and that this effect appears to be specific to alcohol and the mechanisms of alcohol dependence. Acamprosate calcium has negligible observable central nervous system (CNS) activity in animals outside of its effects on alcohol dependence, exhibiting no anticonvulsant, antidepressant, or anxiolytic activity.

# Predicted_LogP_Hydrophobicity:
-1.8

# Predicted_LogS:
-0.98

# Predicted_Water_Solubility:
1.88e+01 g/l

# Primary_Accession_No:
DB00659

# Protein_Binding:
Non detectable

# PubChem_Compound_ID:
71158

# PubChem_Substance_ID:
46506657

# RxList_Link:
http://www.rxlist.com/cgi/generic3/campral.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00661

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)NCCCS(O)(=O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
3-(Acetylamino)propanesulphonic acid
3-Acetamido-1-propanesulfonic acid
N-Acetylhomotaurine

# Synthesis_Reference:
Not Available

# Toxicity:
In all reported cases of acute overdosage with acamprosate (total reported doses of up to 56 grams of acamprosate calcium), the only symptom that could be reasonably associated with acamprosate was diarrhea.

# Update_Date:
2013-02-08 16:19:32 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Acamprosate

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cell membrane
multi-pass membrane protein. Enriched in post-synaptic plasma membrane and post-synap

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17502428	Smothers CT, Woodward JJ: Pharmacological characterization of glycine-activated currents in HEK 293 cells expressing N-methyl-D-aspartate NR1 and NR3 subunits. J Pharmacol Exp Ther. 2007 Aug;322(2):739-48. Epub 2007 May 14.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
GRIN3A

# Drug_Target_1_GenBank_ID_Gene:
AJ416950

# Drug_Target_1_GenBank_ID_Protein:
20372905

# Drug_Target_1_GeneCard_ID:
GRIN3A

# Drug_Target_1_Gene_Name:
GRIN3A

# Drug_Target_1_Gene_Sequence:
>3348 bp
ATGAGGAGACTGAGTTTGTGGTGGCTGCTGAGCAGGGTCTGTCTGCTGTTGCCGCCGCCC
TGCGCACTGGTGCTGGCCGGGGTGCCCAGCTCCTCCTCGCACCCGCAGCCCTGCCAGATC
CTCAAGCGCATCGGGCACGCGGTGAGGGTGGGCGCGGTGCACTTGCAGCCCTGGACCACC
GCCCCCCGCGCGGCCAGCCGCGCTCCGGACGACAGCCGAGCAGGAGCCCAGAGGGATGAG
CCGGAGCCAGGGACTAGGCGGTCCCCGGCGCCCTCGCCGGGCGCACGCTGGTTGGGGAGC
ACCCTGCATGGCCGGGGGCCGCCGGGCTCCCGTAAGCCCGGGGAGGGCGCCAGGGCGGAG
GCCCTGTGGCCACGGGACGCCCTCCTATTTGCCGTGGACAACCTGAACCGCGTGGAAGGG
CTGCTACCCTACAACCTGTCTTTGGAAGTAGTGATGGCCATCGAGGCAGGCCTGGGCGAT
CTGCCACTTTTGCCCTTCTCCTCCCCTAGTTCGCCATGGAGCAGTGACCCTTTCTCCTTC
CTGCAAAGTGTGTGCCATACCGTGGTGGTGCAAGGGGTGTCGGCGCTGCTCGCCTTCCCC
CAGAGCCAGGGCGAAATGATGGAGCTCGACTTGGTCAGCTTAGTCCTGCACATTCCAGTG
ATCAGCATCGTGCGCCACGAGTTTCCGCGGGAGAGTCAGAATCCCCTTCACCTACAACTG
AGTTTAGAAAATTCATTAAGTTCTGATGCTGATGTCACTGTCTCAATCCTGACCATGAAC
AACTGGTACAATTTTAGCTTGTTGCTGTGCCAGGAAGACTGGAACATCACCGACTTCCTC
CTCCTTACCCAGAATAATTCCAAGTTCCACCTTGGTTCTATCATCAACATCACCGCTAAC
CTCCCCTCCACCCAGGACCTCTTGAGCTTCCTACAGATCCAGCTTGAGAGTATTAAGAAC
AGCACACCCACAGTGGTGATGTTTGGCTGCGACATGGAAAGTATCCGGCGGATTTTCGAA
ATTACAACCCAGTTTGGGGTCATGCCCCCTGAACTTCGTTGGGTGCTGGGAGATTCCCAG
AATATGGAGGAACTGAGGACAGAGGGTCTGCCCTTAGGACTCATTGCTCATGGAAAAACA
ACACAGTCTGTCTTTGAGCACTACGTACAAGATGCTATGGAGCTGGTCGCAAGAGCTGTA
GCCACAGCCACCATGATCCAACCAGAACTTGCTCTCATTCCCAGCACGATGAACTGCATG
GAGGTGGAAACTACAAATCTCACTTCAGGACAATATTTATCAAGGTTTCTAGCCAATACC
ACTTTCAGAGGCCTCAGTGGTTCCATCAGAGTAAAAGGTTCCACCATCGTCAGCTCAGAA
AACAACTTTTTCATCTGGAATCTTCAACATGACCCCATGGGAAAGCCAATGTGGACCCGC
TTGGGCAGCTGGCAGGGGAGAAAGATTGTCATGGACTATGGAATATGGCCAGAGCAGGCC
CAGAGACACAAAACCCACTTCCAACATCCAAGTAAGCTACACTTGAGAGTGGTTACCCTG
ATTGAGCATCCTTTTGTCTTCACAAGGGAGGTAGATGATGAAGGCTTGTGCCCTGCTGGC
CAACTCTGTCTAGACCCCATGACTAATGACTCTTCCACACTGGACAGCCTTTTTAGCAGC
CTCCATAGCAGTAATGATACAGTGCCCATTAAATTCAAGAAGTGCTGCTATGGATATTGC
ATTGATCTGCTGGAAAAGATAGCAGAAGACATGAACTTTGACTTCGACCTCTATATTGTA
GGGGATGGAAAGTATGGAGCCTGGAAAAATGGGCACTGGACTGGGCTAGTGGGTGATCTC
CTGAGAGGGACTGCCCACATGGCAGTCACTTCCTTTAGCATCAATACTGCACGGAGCCAG
GTGATAGATTTCACCAGCCCTTTCTTCTCCACCAGCTTGGGCATCTTAGTGAGGACCCGA
GATACAGCAGCTCCCATTGGAGCCTTCATGTGGCCACTCCACTGGACAATGTGGCTGGGG
ATTTTTGTGGCTCTGCACATCACTGCCGTCTTCCTCACTCTGTATGAATGGAAGAGTCCA
TTTGGTTTGACTCCCAAGGGGCGAAATAGAAGTAAAGTCTTCTCCTTTTCTTCAGCCTTG
AACATCTGTTATGCCCTCTTGTTTGGCAGAACAGTGGCCATCAAACCTCCAAAATGTTGG
ACTGGAAGGTTTCTAATGAACCTTTGGGCCATTTTCTGTATGTTTTGCCTTTCCACATAC
ACGGCAAACTTGGCTGCTGTCATGGTAGGTGAGAAGATCTATGAAGAGCTTTCTGGAATA
CATGACCCCAAGTTACATCATCCTTCCCAAGGATTCCGCTTTGGAACTGTCCGAGAAAGC
AGTGCTGAAGATTATGTGAGACAAAGTTTCCCAGAGATGCATGAATATATGAGAAGGTAC
AATGTTCCAGCCACCCCTGATGGAGTGGAGTATCTGAAGAACAATCCAGAGAAACTAGAC
GCCTTCATCATGGACAAAGCCCTTCTGGATTATGAAGTGTCAATAGATGCTGACTGCAAA
CTTCTCACTGTGGGGAAGCCATTTGCCATAGAAGGATACGGCATTGGCCTCCCACCCAAC
TCTCCATTGACCGCCAACATATCCGAGCTAATCAGTCAATACAAGTCACATGGGTTTATG
GATATGCTCCATGACAAGTGGTACAGGGTGGTTCCCTGTGGCAAGAGAAGTTTTGCTGTC
ACGGAGACTTTGCAAATGGGCATCAAACACTTCTCTGGGCTCTTTGTGCTGCTGTGCATT
GGATTTGGTCTGTCCATTTTGACCACCATTGGTGAGCACATAGTATACAGGCTGCTGCTA
CCACGAATCAAAAACAAATCCAAGCTGCAATACTGGCTCCACACCAGCCAGAGATTACAC
AGAGCAATAAATACATCATTTATAGAGGAAAAGCAGCAGCATTTCAAGACCAAACGTGTG
GAAAAGAGGTCTAATGTGGGACCCCGTCAGCTTACCGTATGGAATACTTCCAATCTGAGT
CATGACAACCGACGGAAATACATCTTTAGTGATGAGGAAGGACAAAACCAGCTGGGCATC
CGGATCCACCAGGACATCCCCCTCCCTCCAAGGAGAAGAGAGCTCCCTGCCTTGCGGACC
ACCAATGGGAAAGCAGACTCCCTAAATGTATCTCGGAACTCAGTGATGCAGGAACTCTCA
GAGCTCGAGAAGCAGATTCAGGTGATCCGTCAGGAGCTGCAGCTGGCTGTGAGCAGGAAA
ACGGAGCTGGAGGAGTATCAAAGGACAAGTCGGACTTGTGAGTCCTAG

# Drug_Target_1_General_Function:
Involved in ionotropic glutamate receptor activity

# Drug_Target_1_General_References:
11735224	Andersson O, Stenqvist A, Attersand A, von Euler G: Nucleotide sequence, genomic organization, and chromosomal localization of genes encoding the human NMDA receptor subunits NR3A and NR3B. Genomics. 2001 Dec;78(3):178-84.
11853319	Nagase T, Kikuno R, Ohara O: Prediction of the coding sequences of unidentified human genes. XXII. The complete sequences of 50 new cDNA clones which code for large proteins. DNA Res. 2001 Dec 31;8(6):319-27.
11880201	Eriksson M, Nilsson A, Froelich-Fabre S, Akesson E, Dunker J, Seiger A, Folkesson R, Benedikz E, Sundstrom E: Cloning and expression of the human N-methyl-D-aspartate receptor subunit NR3A. Neurosci Lett. 2002 Mar 22;321(3):177-81.

# Drug_Target_1_HGNC_ID:
HGNC:16767

# Drug_Target_1_HPRD_ID:
09443

# Drug_Target_1_ID:
706

# Drug_Target_1_Locus:
9q31.1

# Drug_Target_1_Molecular_Weight:
125597

# Drug_Target_1_Name:
Glutamate [NMDA] receptor subunit 3A

# Drug_Target_1_Number_of_Residues:
1115

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Methadone Pathway	SMP00408

# Drug_Target_1_Pfam_Domain_Function:
PF00060	Lig_chan

# Drug_Target_1_Protein_Sequence:
>Glutamate [NMDA] receptor subunit 3A precursor
MRRLSLWWLLSRVCLLLPPPCALVLAGVPSSSSHPQPCQILKRIGHAVRVGAVHLQPWTT
APRAASRAPDDSRAGAQRDEPEPGTRRSPAPSPGARWLGSTLHGRGPPGSRKPGEGARAE
ALWPRDALLFAVDNLNRVEGLLPYNLSLEVVMAIEAGLGDLPLLPFSSPSSPWSSDPFSF
LQSVCHTVVVQGVSALLAFPQSQGEMMELDLVSLVLHIPVISIVRHEFPRESQNPLHLQL
SLENSLSSDADVTVSILTMNNWYNFSLLLCQEDWNITDFLLLTQNNSKFHLGSIINITAN
LPSTQDLLSFLQIQLESIKNSTPTVVMFGCDMESIRRIFEITTQFGVMPPELRWVLGDSQ
NMEELRTEGLPLGLIAHGKTTQSVFEHYVQDAMELVARAVATATMIQPELALIPSTMNCM
EVETTNLTSGQYLSRFLANTTFRGLSGSIRVKGSTIVSSENNFFIWNLQHDPMGKPMWTR
LGSWQGRKIVMDYGIWPEQAQRHKTHFQHPSKLHLRVVTLIEHPFVFTREVDDEGLCPAG
QLCLDPMTNDSSTLDSLFSSLHSSNDTVPIKFKKCCYGYCIDLLEKIAEDMNFDFDLYIV
GDGKYGAWKNGHWTGLVGDLLRGTAHMAVTSFSINTARSQVIDFTSPFFSTSLGILVRTR
DTAAPIGAFMWPLHWTMWLGIFVALHITAVFLTLYEWKSPFGLTPKGRNRSKVFSFSSAL
NICYALLFGRTVAIKPPKCWTGRFLMNLWAIFCMFCLSTYTANLAAVMVGEKIYEELSGI
HDPKLHHPSQGFRFGTVRESSAEDYVRQSFPEMHEYMRRYNVPATPDGVEYLKNNPEKLD
AFIMDKALLDYEVSIDADCKLLTVGKPFAIEGYGIGLPPNSPLTANISELISQYKSHGFM
DMLHDKWYRVVPCGKRSFAVTETLQMGIKHFSGLFVLLCIGFGLSILTTIGEHIVYRLLL
PRIKNKSKLQYWLHTSQRLHRAINTSFIEEKQQHFKTKRVEKRSNVGPRQLTVWNTSNLS
HDNRRKYIFSDEEGQNQLGIRIHQDIPLPPRRRELPALRTTNGKADSLNVSRNSVMQELS
ELEKQIQVIRQELQLAVSRKTELEEYQRTSRTCES

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-23

# Drug_Target_1_Specific_Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism

# Drug_Target_1_SwissProt_ID:
Q8TCU5

# Drug_Target_1_SwissProt_Name:
NMD3A_HUMAN

# Drug_Target_1_Synonyms:
Glutamate receptor subunit 3A precursor
N-methyl-D-aspartate receptor subtype NR3A
NMDAR-L

# Drug_Target_1_Theoretical_pI:
7.81

# Drug_Target_1_Transmembrane_Regions:
675-695
749-769
931-951

# Drug_Target_2_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
15963001	De Witte P, Littleton J, Parot P, Koob G: Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs. 2005;19(6):517-37.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
GRM5

# Drug_Target_2_GenBank_ID_Gene:
D28538

# Drug_Target_2_GenBank_ID_Protein:
1408052

# Drug_Target_2_GeneCard_ID:
GRM5

# Drug_Target_2_Gene_Name:
GRM5

# Drug_Target_2_Gene_Sequence:
>3543 bp
ATGGTCCTTCTGTTGATCCTGTCAGTCTTACTTTTGAAAGAAGATGTCCGTGGGAGTGCA
CAGTCCAGTGAGAGGAGGGTGGTGGCTCACATGCCGGGTGACATCATTATTGGAGCTCTC
TTTTCTGTTCATCACCAGCCTACTGTGGACAAAGTTCATGAGAGGAAGTGTGGGGCGGTC
CGTGAACAGTATGGCATTCAGAGAGTGGAGGCCATGCTGCATACCCTGGAAAGGATCAAT
TCAGACCCCACACTCTTGCCCAACATCACACTGGGCTGTGAGATAAGGGACTCCTGCTGG
CATTCGGCTGTGGCCCTAGAGCAGAGCATTGAGTTCATAAGAGATTCCCTCATTTCTTCA
GAAGAGGAAGAAGGCTTGGTACGCTGTGTGGATGGCTCCTCCTCTTCCTTCCGCTCCAAG
AAGCCCATAGTAGGGGTCATTGGGCCTGGCTCCAGTTCTGTAGCCATTCAGGTCCAGAAT
TTGCTCCAGCTTTTCAACATACCTCAGATTGCTTACTCAGCAACCAGCATGGATCTGAGT
GACAAGACTCTGTTCAAATATTTCATGAGGGTTGTGCCTTCAGATGCTCAGCAGGCAAGG
GCCATGGTGGACATAGTGAAGAGGTACAACTGGACCTATGTATCAGCCGTGCACACAGAA
GGCAACTATGGAGAAAGTGGGATGGAAGCCTTCAAAGATATGTCAGCGAAGGAAGGGATT
TGCATCGCCCACTCTTACAAAATCTACAGTAATGCAGGGGAGCAGAGCTTTGATAAGCTG
CTGAAGAAGCTCACAAGTCACTTGCCCAAGGCCCGGGTGGTGGCCTGCTTCTGTGAGGGC
ATGACGGTGAGAGGTCTGCTGATGGCCATGAGGCGCCTGGGTCTAGCGGGAGAATTTCTG
CTTCTGGGCAGTGATGGCTGGGCTGACAGGTATGATGTGACAGATGGATATCAGCGAGAA
GCTGTTGGTGGCATCACAATCAAGCTCCAATCTCCCGATGTCAAGTGGTTTGATGATTAT
TATCTGAAGCTCCGGCCAGAAACAAACCACCGAAACCCTTGGTTTCAAGAATTTTGGCAG
CATCGTTTTCAGTGCCGACTGGAAGGGTTTCCACAGGAGAACAGCAAATACAACAAGACT
TGCAATAGTTCTCTGACTCTGAAAACACATCATGTTCAGGATTCCAAAATGGGATTTGTG
ATCAACGCCATCTATTCGATGGCCTATGGGCTCCACAACATGCAGATGTCCCTCTGCCCA
GGCTATGCAGGACTCTGTGATGCCATGAAGCCAATTGATGGACGGAAACTTTTGGAGTCC
CTGATGAAAACCAATTTTACTGGGGTTTCTGGAGATACGATCCTATTCGATGAGAATGGA
GACTCTCCAGGAAGGTATGAAATAATGAATTTCAAGGAAATGGGAAAAGATTACTTTGAT
TATATCAACGTTGGAAGTTGGGACAATGGAGAATTAAAAATGGATGATGATGAAGTATGG
TCCAAGAAAAGCAACATCATCAGATCTGTGTGCAGTGAACCATGTGAGAAAGGCCAGATC
AAGGTGATCCGAAAGGGAGAAGTCAGCTGTTGTTGGACCTGTACACCTTGTAAGGAGAAT
GAGTATGTCTTTGATGAGTACACATGCAAGGCATGCCAACTGGGGTCTTGGCCCACTGAT
GATCTCACAGGTTGTGACTTGATCCCAGTACAGTATCTTCGATGGGGTGACCCTGAACCC
ATTGCAGCTGTGGTGTTTGCCTGCCTTGGCCTCCTGGCCACCCTGTTTGTTACTGTAGTC
TTCATCATTTACCGTGATACACCAGTAGTCAAGTCCTCAAGCAGGGAACTCTGCTACATT
ATCCTTGCTGGCATCTGCCTGGGCTACTTATGTACCTTCTGCCTCATTGCGAAGCCCAAA
CAGATTTACTGCTACCTTCAGAGAATTGGCATTGGTCTCTCCCCAGCCATGAGCTACTCA
GCCCTTGTAACAAAGACCAACCGTATTGCAAGGATCCTGGCTGGCAGCAAGAAGAAGATC
TGTACCAAAAAGCCCAGATTCATGAGTGCCTGTGCCCAGCTAGTGATTGCTTTCATTCTC
ATATGCATCCAGTTGGGCATCATCGTTGCCCTCTTTATAATGGAGCCTCCTGACATAATG
CATGACTACCCAAGCATTCGAGAAGTCTACCTGATCTGTAACACCACCAACCTAGGAGTT
GTCACTCCACTTGGATACAATGGATTGTTGATTTTGAGCTGCACCTTCTATGCGTTCAAG
ACCAGAAATGTTCCAGCTAACTTCAACGAGGCCAAGTATATCGCCTTCACAATGTACACG
ACCTGCATTATATGGCTAGCTTTTGTGCCAATCTACTTTGGCAGCAACTACAAAATCATC
ACCATGTGTTTCTCGGTCAGCCTCAGTGCCACAGTGGCCCTAGGCTGCATGTTTGTGCCG
AAGGTGTACATCATCCTGGCCAAACCAGAGAGAAACGTGCGCAGCGCCTTCACCACATCT
ACCGTGGTGCGCATGCATGTAGGGGATGGCAAGTCATCCTCCGCAGCCAGCAGATCCAGC
AGCCTAGTCAACCTGTGGAAGAGAAGGGGCTCCTCTGGGGAAACCTTAAGTTCCAATGGA
AAATCCGTCACGTGGGCCCAGAATGAGAAGAGCAGCCGGGGGCAGCACCTGTGGCAGCGC
CTGTCCATCCACATCAACAAGAAAGAAAACCCCAACCAAACGGCCGTCATCAAGCCCTTC
CCCAAGAGCACGGAGAGCCGTGGCCTGGGCGCTGGCGCTGGCGCAGGCGGGAGCGCTGGG
GGCGTGGGGGCCACGGGCGGTGCGGGCTGCGCAGGCGCCGGCCCAGGCGGGCCCGAGTCC
CCAGACGCCGGCCCCAAGGCGCTGTATGATGTGGCCGAGGCTGAGGAGCACTTCCCGGCG
CCCGCGCGGCCGCGCTCACCGTCGCCCATCAGCACGCTGAGCCACCGCGCGGGCTCGGCC
AGCCGCACGGACGACGATGTGCCGTCGCTGCACTCGGAGCCTGTGGCGCGCAGCAGCTCC
TCGCAGGGCTCCCTCATGGAGCAGATCAGCAGTGTGGTCACCCGCTTCACGGCCAACATC
AGCGAGCTCAACTCCATGATGCTGTCCACCGCGGCCCCCAGCCCCGGCGTCGGCGCCCCG
CTCTGCTCGTCCTACCTGATCCCCAAAGAGATCCAGTTGCCCACGACCATGACGACCTTT
GCCGAAATCCAGCCTCTGCCGGCCATCGAAGTCACGGGCGGCGCGCAGCCCGCGGCAGGG
GCGCAGGCGGCTGGGGACGCGGCCCGGGAGAGCCCCGCGGCCGGTCCCGAGGCTGCGGCC
GCCAAGCCAGACCTGGAGGAGCTGGTGGCTCTCACCCCGCCGTCCCCCTTCAGAGACTCG
GTGGACTCGGGGAGCACAACCCCCAACTCGCCAGTGTCCGAGTCGGCCCTCTGTATCCCG
TCGTCTCCCAAATATGACACTCTTATCATAAGAGATTACACTCAGAGCTCCTCGTCGTTG
TGA

# Drug_Target_2_General_Function:
Involved in metabotropic glutamate, GABA-B-like receptor activity

# Drug_Target_2_General_References:
7688218	Minakami R, Katsuki F, Sugiyama H: A variant of metabotropic glutamate receptor subtype 5: an evolutionally conserved insertion with no termination codon. Biochem Biophys Res Commun. 1993 Jul 30;194(2):622-7.
7908515	Minakami R, Katsuki F, Yamamoto T, Nakamura K, Sugiyama H: Molecular cloning and the functional expression of two isoforms of human metabotropic glutamate receptor subtype 5. Biochem Biophys Res Commun. 1994 Mar 30;199(3):1136-43.

# Drug_Target_2_HGNC_ID:
HGNC:4597

# Drug_Target_2_HPRD_ID:
04980

# Drug_Target_2_ID:
2178

# Drug_Target_2_Locus:
11q14.2-q14.3

# Drug_Target_2_Molecular_Weight:
132470

# Drug_Target_2_Name:
Metabotropic glutamate receptor 5

# Drug_Target_2_Number_of_Residues:
1212

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00003	7tm_3
PF01094	ANF_receptor
PF07562	NCD3G

# Drug_Target_2_Protein_Sequence:
>Metabotropic glutamate receptor 5 precursor
MVLLLILSVLLLKEDVRGSAQSSERRVVAHMPGDIIIGALFSVHHQPTVDKVHERKCGAV
REQYGIQRVEAMLHTLERINSDPTLLPNITLGCEIRDSCWHSAVALEQSIEFIRDSLISS
EEEEGLVRCVDGSSSSFRSKKPIVGVIGPGSSSVAIQVQNLLQLFNIPQIAYSATSMDLS
DKTLFKYFMRVVPSDAQQARAMVDIVKRYNWTYVSAVHTEGNYGESGMEAFKDMSAKEGI
CIAHSYKIYSNAGEQSFDKLLKKLTSHLPKARVVACFCEGMTVRGLLMAMRRLGLAGEFL
LLGSDGWADRYDVTDGYQREAVGGITIKLQSPDVKWFDDYYLKLRPETNHRNPWFQEFWQ
HRFQCRLEGFPQENSKYNKTCNSSLTLKTHHVQDSKMGFVINAIYSMAYGLHNMQMSLCP
GYAGLCDAMKPIDGRKLLESLMKTNFTGVSGDTILFDENGDSPGRYEIMNFKEMGKDYFD
YINVGSWDNGELKMDDDEVWSKKSNIIRSVCSEPCEKGQIKVIRKGEVSCCWTCTPCKEN
EYVFDEYTCKACQLGSWPTDDLTGCDLIPVQYLRWGDPEPIAAVVFACLGLLATLFVTVV
FIIYRDTPVVKSSSRELCYIILAGICLGYLCTFCLIAKPKQIYCYLQRIGIGLSPAMSYS
ALVTKTNRIARILAGSKKKICTKKPRFMSACAQLVIAFILICIQLGIIVALFIMEPPDIM
HDYPSIREVYLICNTTNLGVVTPLGYNGLLILSCTFYAFKTRNVPANFNEAKYIAFTMYT
TCIIWLAFVPIYFGSNYKIITMCFSVSLSATVALGCMFVPKVYIILAKPERNVRSAFTTS
TVVRMHVGDGKSSSAASRSSSLVNLWKRRGSSGETLRYKDRRLAQHKSEIECFTPKGSMG
NGGRATMSSSNGKSVTWAQNEKSSRGQHLWQRLSIHINKKENPNQTAVIKPFPKSTESRG
LGAGAGAGGSAGGVGATGGAGCAGAGPGGPESPDAGPKALYDVAEAEEHFPAPARPRSPS
PISTLSHRAGSASRTDDDVPSLHSEPVARSSSSQGSLMEQISSVVTRFTANISELNSMML
STAAPSPGVGAPLCSSYLIPKEIQLPTTMTTFAEIQPLPAIEVTGGAQPAAGAQAAGDAA
RESPAAGPEAAAAKPDLEELVALTPPSPFRDSVDSGSTTPNSPVSESALCIPSSPKYDTL
IIRDYTQSSSSL

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-20

# Drug_Target_2_Specific_Function:
Receptor for glutamate. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol- calcium second messenger system and generates a calcium-activated chloride current

# Drug_Target_2_SwissProt_ID:
P41594

# Drug_Target_2_SwissProt_Name:
GRM5_HUMAN

# Drug_Target_2_Synonyms:
Metabotropic glutamate receptor 5 precursor
mGluR5

# Drug_Target_2_Theoretical_pI:
7.82

# Drug_Target_2_Transmembrane_Regions:
580-602
617-637
649-667
694-714
738-759
773-795
802-827

# Drug_Target_3_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
GRM1

# Drug_Target_3_GenBank_ID_Gene:
U31215

# Drug_Target_3_GenBank_ID_Protein:
945097

# Drug_Target_3_GeneCard_ID:
GRM1

# Drug_Target_3_Gene_Name:
GRM1

# Drug_Target_3_Gene_Sequence:
>3585 bp
ATGGTCGGGCTCCTTTTGTTTTTTTTCCCAGCGATCTTTTTGGAGGTGTCCCTTCTCCCC
AGAAGCCCCGGCAGGAAAGTGTTGCTGGCAGGAGCGTCGTCTCAGCGCTCGGTGGCCAGA
ATGGACGGAGATGTCATCATTGGAGCCCTCTTCTCAGTCCATCACCAGCCTCCGGCCGAG
AAAGTGCCCGAGAGGAAGTGTGGGGAGATCAGGGAGCAGTATGGCATCCAGAGGGTGGAG
GCCATGTTCCACACGTTGGATAAGATCAACGCGGACCCGGTCCTCCTGCCCAACATCACC
CTGGGCAGTGAGATCCGGGACTCCTGCTGGCACTCTTCCGTGGCTCTGGAACAGAGCATT
GAGTTCATTAGGGACTCTCTGATTTCCATTCGAGATGAGAAGGATGGGATCAACCGGTGT
CTGCCTGACGGCCAGTCCCTCCCCCCAGGCAGGACTAAGAAGCCCATTGCGGGAGTGATC
GGTCCCGGCTCCAGCTCTGTAGCCATTCAAGTGCAGAACCTGCTCCAGCTCTTCGACATC
CCCCAGATCGCTTATTCAGCCACAAGCATCGACCTGAGTGACAAAACTTTGTACAAATAC
TTCCTGAGGGTTGTCCCTTCTGACACTTTGCAGGCAAGGGCCATGCTTGACATAGTCAAA
CGTTACAATTGGACCTATGTCTCTGCAGTCCACACGGAAGGGAATTATGGGGAGAGCGGA
ATGGACGCTTTCAAAGAGCTGGCTGCCCAGGAAGGCCTCTGTATCGCCCATTCTGACAAA
ATCTACAGCAACGCTGGGGAGAAGAGCTTTGACCGACTCTTGCGCAAACTCCGAGAGAGG
CTTCCCAAGGCTAGAGTGGTGGTCTGCTTCTGTGAAGGCATGACAGTGCGAGGACTCCTG
AGCGCCATGCGGCGCCTTGGCGTCGTGGGCGAGTTCTCACTCATTGGAAGTGATGGATGG
GCAGACAGAGATGAAGTCATTGAAGGTTATGAGGTGGAAGCCAACGGGGGAATCACGATA
AAGCTGCAGTCTCCAGAGGTCAGGTCATTTGATGATTATTTCCTGAAACTGAGGCTGGAC
ACTAACACGAGGAATCCCTGGTTCCCTGAGTTCTGGCAACATCGGTTCCAGTGCCGCCTT
CCAGGACACCTTCTGGAAAATCCCAACTTTAAACGAATCTGCACAGGCAATGAAAGCTTA
GAAGAAAACTATGTCCAGGACAGTAAGATGGGGTTTGTCATCAATGCCATCTATGCCATG
GCACATGGGCTGCAGAACATGCACCATGCCCTCTGCCCTGGCCACGTGGGCCTCTGCGAT
GCCATGAAGCCCATCGACGGCAGCAAGCTGCTGGACTTCCTCATCAAGTCCTCATTCATT
GGAGTATCTGGAGAGGAGGTGTGGTTTGATGAGAAAGGAGACGCTCCTGGAAGGTATGAT
ATCATGAATCTGCAGTACACTGAAGCTAATCGCTATGACTATGTGCACGTTGGAACCTGG
CATGAAGGAGTGCTGAACATTGATGATTACAAAATCCAGATGAACAAGAGTGGAGTGGTG
CGGTCTGTGTGCAGTGAGCCTTGCTTAAAGGGCCAGATTAAGGTTATACGGAAAGGAGAA
GTGAGCTGCTGCTGGATTTGCACGGCCTGCAAAGAGAATGAATATGTGCAAGATGAGTTC
ACCTGCAAAGCTTGTGACTTGGGATGGTGGCCCAATGCAGATCTAACAGGCTGTGAGCCC
ATTCCTGTGCGCTATCTTGAGTGGAGCAACATCGAACCCATTATAGCCATCGCCTTTTCA
TGCCTGGGAATCCTTGTTACCTTGTTTGTCACCCTAATCTTTGTACTGTACCGGGACACA
CCAGTGGTCAAATCCTCCAGTCGGGAGCTCTGCTACATCATCCTAGCTGGCATCTTCCTT
GGTTATGTGTGCCCATTCACTCTCATTGCCAAACCTACTACCACCTCCTGCTACCTCCAG
CGCCTCTTGGTTGGCCTCTCCTCTGCGATGTGCTACTCTGCTTTAGTGACTAAAACCAAT
CGTATTGCACGCATCCTGGCTGGCAGCAAGAAGAAGATCTGCACCCGGAAGCCCAGGTTC
ATGAGTGCCTGGGCTCAGGTGATCATTGCCTCAATTCTGATTAGTGTGCAACTAACCCTG
GTGGTAACCCTGATCATCATGGAACCCCCTATGCCCATTCTGTCCTACCCAAGTATCAAG
GAAGTCTACCTTATCTGCAATACCAGCAACCTGGGTGTGGTGGCCCCTTTGGGCTACAAT
GGACTCCTCATCATGAGCTGTACCTACTATGCCTTCAAGACCCGCAACGTGCCCGCCAAC
TTCAACGAGGCCAAATATATCGCGTTCACCATGTACACCACCTGTATCATCTGGCTAGCT
TTTGTGCCCATTTACTTTGGGAGCAACTACAAGATCATCACAACTTGCTTTGCAGTGAGT
CTCAGTGTAACAGTGGCTCTGGGGTGCATGTTCACTCCCAAGATGTACATCATTATTGCC
AAGCCTGAGAGGAATGTCCGCAGTGCCTTCACCACCTCTGATGTTGTCCGCATGCATGTT
GGCGATGGCAAGCTGCCCTGCCGCTCCAACACTTTCCTCAACATCTTCCGAAGAAAGAAG
GCAGGGGCAGGGAATGCCAATTCTAATGGCAAGTCTGTGTCATGGTCTGAACCAGGTGGA
GGACAGGTGCCCAAGGGACAGCATATGTGGCACCGCCTCTCTGTGCACGTGAAGACCAAT
GAGACGGCCTGCAACCAAACAGCCGTCATCAAACCCCTCACTAAAAGTTACCAAGGCTCT
GGCAAGAGCCTGACCTTTTCAGATACCAGCACCAAGACCCTTTACAACGTAGAGGAGGAG
GAGGATGCCCAGCCGATTCGCTTTAGCCCGCCTGGTAGCCCTTCCATGGTGGTGCACAGG
CGCGTGCCAAGCGCGGCGACCACTCCGCCTCTGCCGCCCCACCTGACCGCAGAGGAGACC
CCCCTCTTCCTGGCCGAACCAGCCCTCCCCAAGGGCTTGCCCCCTCCTCTCCAGCAGCAG
CAGCAACCCCCTCCACAGCAGAAATCGCTGATGGACCAGCTCCAGGGAGTGGTCAGCAAC
TTCAGTACCGCGATCCCGGATTTTCACGCGGTGCTGGCAGGCCCCGGGGGTCCCGGGAAC
GGGCTGCGGTCCCTGTACCCGCCCCCGCCACCTCCGCAGCACCTGCAGATGCTGCCGCTG
CAGCTGAGCACCTTTGGGGAGGAGCTGGTCTCCCCGCCCGCGGACGACGACGACGACAGC
GAGAGGTTTAAGCTCCTCCAGGAGTACGTGTATGAGCACGAGCGGGAAGGGAACACCGAA
GAAGACGAACTGGAAGAGGAGGAGGAGGACCTGCAGGCGGCCAGCAAACTGACCCCGGAT
GATTCGCCTGCGCTGACGCCTCCGTCGCCTTTCCGCGACTCGGTGGCCTCGGGCAGCTCG
GTGCCCAGCTCCCCAGTGTCCGAGTCGGTGCTCTGCACCCCTCCCAACGTATCCTACGCC
TCTGTCATTCTGCGGGACTACAAGCAAAGCTCTTCCACCCTGTAA

# Drug_Target_3_General_Function:
Involved in metabotropic glutamate, GABA-B-like receptor activity

# Drug_Target_3_General_References:
10945991	Ray K, Hauschild BC: Cys-140 is critical for metabotropic glutamate receptor-1 dimerization. J Biol Chem. 2000 Nov 3;275(44):34245-51.
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
7476890	Desai MA, Burnett JP, Mayne NG, Schoepp DD: Cloning and expression of a human metabotropic glutamate receptor 1 alpha: enhanced coupling on co-transfection with a glutamate transporter. Mol Pharmacol. 1995 Oct;48(4):648-57.
9076744	Stephan D, Bon C, Holzwarth JA, Galvan M, Pruss RM: Human metabotropic glutamate receptor 1: mRNA distribution, chromosome localization and functional expression of two splice variants. Neuropharmacology. 1996;35(12):1649-60.

# Drug_Target_3_HGNC_ID:
HGNC:4593

# Drug_Target_3_HPRD_ID:
05129

# Drug_Target_3_ID:
916

# Drug_Target_3_Locus:
6q24

# Drug_Target_3_Molecular_Weight:
132368

# Drug_Target_3_Name:
Metabotropic glutamate receptor 1

# Drug_Target_3_Number_of_Residues:
1194

# Drug_Target_3_PDB_ID:
1ISS

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00003	7tm_3
PF01094	ANF_receptor
PF07562	NCD3G

# Drug_Target_3_Protein_Sequence:
>Metabotropic glutamate receptor 1 precursor
MVGLLLFFFPAIFLEVSLLPRSPGRKVLLAGASSQRSVARMDGDVIIGALFSVHHQPPAE
KVPERKCGEIREQYGIQRVEAMFHTLDKINADPVLLPNITLGSEIRDSCWHSSVALEQSI
EFIRDSLISIRDEKDGINRCLPDGQSLPPGRTKKPIAGVIGPGSSSVAIQVQNLLQLFDI
PQIAYSATSIDLSDKTLYKYFLRVVPSDTLQARAMLDIVKRYNWTYVSAVHTEGNYGESG
MDAFKELAAQEGLCIAHSDKIYSNAGEKSFDRLLRKLRERLPKARVVVCFCEGMTVRGLL
SAMRRLGVVGEFSLIGSDGWADRDEVIEGYEVEANGGITIKLQSPEVRSFDDYFLKLRLD
TNTRNPWFPEFWQHRFQCRLPGHLLENPNFKRICTGNESLEENYVQDSKMGFVINAIYAM
AHGLQNMHHALCPGHVGLCDAMKPIDGSKLLDFLIKSSFIGVSGEEVWFDEKGDAPGRYD
IMNLQYTEANRYDYVHVGTWHEGVLNIDDYKIQMNKSGVVRSVCSEPCLKGQIKVIRKGE
VSCCWICTACKENEYVQDEFTCKACDLGWWPNADLTGCEPIPVRYLEWSNIESIIAIAFS
CLGILVTLFVTLIFVLYRDTPVVKSSSRELCYIILAGIFLGYVCPFTLIAKPTTTSCYLQ
RLLVGLSSAMCYSALVTKTNRIARILAGSKKKICTRKPRFMSAWAQVIIASILISVQLTL
VVTLIIMEPPMPILSYPSIKEVYLICNTSNLGVVAPLGYNGLLIMSCTYYAFKTRNVPAN
FNEAKYIAFTMYTTCIIWLAFVPIYFGSNYKIITTCFAVSLSVTVALGCMFTPKMYIIIA
KPERNVRSAFTTSDVVRMHVGDGKLPCRSNTFLNIFRRKKAGAGNANSNGKSVSWSEPGG
GQVPKGQHMWHRLSVHVKTNETACNQTAVIKPLTKSYQGSGKSLTFSDTSTKTLYNVEEE
EDAQPIRFSPPGSPSMVVHRRVPSAATTPPLPPHLTAEETPLFLAEPALPKGLPPPLQQQ
QQPPPQQKSLMDQLQGVVSNFSTAIPDFHAVLAGPGGPGNGLRSLYPPPPPPQHLQMLPL
QLSTFGEELVSPPADDDDDSERFKLLQEYVYEHEREGNTEEDELEEEEEDLQAASKLTPD
DSPALTPPSPFRDSVASGSSVPSSPVSESVLCTPPNVSYASVILRDYKQSSSTL

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-18

# Drug_Target_3_Specific_Function:
Receptor for glutamate. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol- calcium second messenger system. May participate in the central action of glutamate in the CNS, such as long-term potentiation in the hippocampus and long-term depression in the cerebellum

# Drug_Target_3_SwissProt_ID:
Q13255

# Drug_Target_3_SwissProt_Name:
GRM1_HUMAN

# Drug_Target_3_Synonyms:
Metabotropic glutamate receptor 1 precursor
mGluR1

# Drug_Target_3_Theoretical_pI:
6.67

# Drug_Target_3_Transmembrane_Regions:
593-615
630-650
662-680
707-727
751-772
786-808
815-840

# Drug_Target_4_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
16545872	Heilig M, Egli M: Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006 Sep;111(3):855-76. Epub 2006 Mar 20.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
GRM2

# Drug_Target_4_GenBank_ID_Gene:
L35318

# Drug_Target_4_GenBank_ID_Protein:
999416

# Drug_Target_4_GeneCard_ID:
GRM2

# Drug_Target_4_Gene_Name:
GRM2

# Drug_Target_4_Gene_Sequence:
>2619 bp
ATGGGATCGCTGCTTGCGCTCCTGGCACTGCTGCCGCTGTGGGGTGCTGTGGCTGAGGGC
CCAGCCAAGAAGGTGCTGACCCTGGAGGGAGACTTGGTGCTGGGTGGGCTGTTCCCAGTG
CACCAGAAGGGCGGCCCAGCAGAGGACTGTGGTCCTGTCAATGAGCACCGTGGCATCCAG
CGCCTGGAGGCCATGCTTTTTGCACTGGACCGCATCAACCGTGACCCGCACCTGCTGCCT
GGCGTGCGCCTGGGTGCACACATCCTCGACAGTTGCTCCAAGGACACACATGCGCTGGAG
CAGGCACTGGACTTTGTGCGTGCCTCACTCAGCCGTGGTGCTGATGGATCACGCCACATC
TGCCCCGACGGCTCTTATGCGACCCATGGTGATGCTCCCACTGCCATCACTGGTGTTATT
GGCGGTTCCTACAGTGATGTCTCCATCCAGGTGGCCAACCTCTTGAGGCTATTTCAGATC
CCACAGATTAGCTACGCCTCTACCAGTGCCAAGCTGAGTGACAAGTCCCGCTATGACTAC
TTTGCCCGCACAGTGCCTCCTGACTTCTTCCAAGCCAAGGCCATGGCTGAGATTCTCCGC
TTCTTCAACTGGACCTATGTGTCCACTGAGGCCTCTGAGGGCGACTATGGCGAGACAGGC
ATTGAGGCCTTTGAGCTAGAGGCTCGTGCCCGCAACATCTGTGTGGCCACCTCGGAGAAA
GTGGGCCGTGCCATGAGCCGCGCGGCCTTTGAGGGTGTGGTGCGAGCCCTGCTGCAGAAG
CCCAGTGCCCGCGTGGCTGTCCTGTTCACCCGTTCTGAGGATGCCCGGGAGCTGCTTGCT
GCCAGCCAGCGCCTCAATGCCAGCTTCACCTGGGTGGCCAGTGATGGTTGGGGGGCCCTG
GAGAGTGTGGTGGCAGGCAGTGAGGGGGCTGCTGAGGGTGCTATCACCATCGAGCTGGCC
TCCTACCCCATCAGTGACTTTGCCTCCTACTTCCAGAGCCTGGACCCTTGGAACAACAGC
CGGAACCCCTGGTTCCGTGAATTCTGGGAGCAGAGGTTCCGCTGCAGCTTCCGGCAGCGA
GACTGCGCAGCCCACTCTCTCCGGGCTGTGCCCTTTGAACAGGAGTCCAAGATCATGTTT
GTGGTCAATGCAGTGTACGCCATGGCCCATGCGCTCCACAACATGCACCGTGCCCTCTGC
CCCAACACCACCCGGCTCTGTGACGCGATGCGGCCAGTTAACGGGCGCCGCCTCTACAAG
GACTTTGTGCTCAACGTCAAGTTTGATGCCCCCTTTCGCCCAGCTGACACCCACAATGAG
GTCCGCTTTGACCGCTTTGGTGATGGTATTGGCCGCTACAACATCTTCACCTATCTGCGT
GCAGGCAGTGGGCGCTATCGCTACCAGAAGGTGGGCTACTGGGCAGAAGGCTTGACTCTG
GACACCAGCCTCATCCCATGGGCCTCACCGTCAGCCGGCCCCCTGGCCGCCTCTCGCTGC
AGTGAGCCCTGCCTCCAGAATGAGGTGAAGAGTGTGCAGCCGGGCGAAGTCTGCTGCTGG
CTCTGCATTCCGTGCCAGCCCTATGAGTACCGATTGGACGAATTCACTTGCGCTGATTGT
GGCCTGGGCTACTGGCCCAATGCCAGCCTGACTGGCTGCTTCGAACTGCCCCAGGAGTAC
ATCCGCTGGGGCGATGCCTGGGCTGTGGGACCTGTCACCATCGCCTGCCTCGGTGCCCTG
GCCACCCTGTTTGTGCTGGGTGTCTTTGTGCGGCACAATGCCACACCAGTGGTCAAGGCC
TCAGGTCGGGAGCTCTGCTACATCCTGCTGGGTGGTGTCTTCCTCTGCTACTGCATGACC
TTCATCTTCATTGCCAAGCCATCCACGGCAGTGTGTACCTTACGGCGTCTTGGTTTGGGC
ACTGCCTTCTCTGTCTGCTACTCAGCCCTGCTCACCAAGACCAACCGCATTGCACGCATC
TTCGGTGGGGCCCGGGAGGGTGCCCAGCGGCCACGCTTCATCAGTCCTGCCTCACAGGTG
GCCATCTGCCTGGCACTTATCTCGGGCCAGCTGCTCATCGTGGTCGCCTGGCTGGTGGTG
GAGGCACCGGGCACAGGCAAGGAGACAGCCCCCGAACGGCGGGAGGTGGTGACACTGCGC
TGCAACCACCGCGATGCAAGTATGTTGGGCTCGCTGGCCTACAATGTGCTCCTCATCGCG
CTCTGCACGCTTTATGCCTTCAATACTCGCAAGTGCCCCGAAAACTTCAACGAGGCCAAG
TTCATTGGCTTCACCATGTACACCACCTGCATCATCTGGCTGGCATTGTTGCCCATCTTC
TATGTCACCTCCAGTGACTACCGGGTACAGACCACCACCATGTGCGTGTCAGTCAGCCTC
AGCGGCTCCGTGGTGCTTGGCTGCCTCTTTGCGCCCAAGCTGCACATCATCCTCTTCCAG
CCGCAGAAGAACGTGGTTAGCCACCGGGCACCCACCAGCCGCTTTGGCAGTGCTGCTGCC
AGGGCCAGCTCCAGCCTTGGCCAAGGGTCTGGCTCCCAGTTTGTCCCCACTGTTTGCAAT
GGCCGTGAGGTGGTGGACTCGACAACGTCATCGCTTTGA

# Drug_Target_4_General_Function:
Amino acid transport and metabolism

# Drug_Target_4_General_References:
7620613	Flor PJ, Lindauer K, Puttner I, Ruegg D, Lukic S, Knopfel T, Kuhn R: Molecular cloning, functional expression and pharmacological characterization of the human metabotropic glutamate receptor type 2. Eur J Neurosci. 1995 Apr 1;7(4):622-9.

# Drug_Target_4_HGNC_ID:
HGNC:4594

# Drug_Target_4_HPRD_ID:
04977

# Drug_Target_4_ID:
1362

# Drug_Target_4_Locus:
3p21.1

# Drug_Target_4_Molecular_Weight:
95569

# Drug_Target_4_Name:
Metabotropic glutamate receptor 2

# Drug_Target_4_Number_of_Residues:
872

# Drug_Target_4_PDB_ID:
Not Available

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00003	7tm_3
PF01094	ANF_receptor
PF07562	NCD3G

# Drug_Target_4_Protein_Sequence:
>Metabotropic glutamate receptor 2 precursor
MGSLLALLALLLLWGAVAEGPAKKVLTLEGDLVLGGLFPVHQKGGPAEDCGPVNEHRGIQ
RLEAMLFALDRINRDPHLLPGVRLGAHILDSCSKDTHALEQALDFVRASLSRGADGSRHI
CPDGSYATHGDAPTAITGVIGGSYSDVSIQVANLLRLFQIPQISYASTSAKLSDKSRYDY
FARTVPPDFFQAKAMAEILRFFNWTYVSTVASEGDYGETGIEAFELEARARNICVATSEK
VGRAMSRAAFEGVVRALLQKPSARVAVLFTRSEDARELLAASQRLNASFTWVASDGWGAL
ESVVAGSEGAAEGAITIELASYPISDFASYFQSLDPWNNSRNPWFREFWEQRFRCSFRQR
DCAAHSLRAVPFEQESKIMFVVNAVYAMAHALHNMHRALCPNTTRLCDAMRPVNGRRLYK
DFVLNVKFDAPFRPADTHNEVRFDRFGDGIGRYNIFTYLRAGSGRYRYQKVGYWAEGLTL
DTSLIPWASPSAGPLPASRCSEPCLQNEVKSVQPGEVCCWLCIPCQPYEYRLDEFTCADC
GLGYWPNASLTGCFELPQEYIRWGDAWAVGPVTIACLGALATLFVLGVFVRHNATPVVKA
SGRELCYILLGGVFLCYCMTFIFIAKPSTAVCTLRRLGLGTAFSVCYSALLTKTNRIARI
FGGAREGAQRPRFISPASQVAICLALISGQLLIVVAWLVVEAPGTGKETAPERREVVTLR
CNHRDASMLGSLAYNVLLIALCTLYAFKTRKCPENFNEAKFIGFTMYTTCIIWLAFLPIF
YVTSSDYRVQTTTMCVSVSLSGSVVLGCLFAPKLHIILFQPQKNVVSHRAPTSRFGSAAA
RASSSLGQGSGSQFVPTVCNGREVVDSTTSSL

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
1-18

# Drug_Target_4_Specific_Function:
Receptor for glutamate. The activity of this receptor is mediated by a G-protein that inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization

# Drug_Target_4_SwissProt_ID:
Q14416

# Drug_Target_4_SwissProt_Name:
GRM2_HUMAN

# Drug_Target_4_Synonyms:
Metabotropic glutamate receptor 2 precursor
mGluR2

# Drug_Target_4_Theoretical_pI:
8.16

# Drug_Target_4_Transmembrane_Regions:
568-590
605-625
637-655
680-700
726-747
761-783
794-819

# Drug_Target_5_Cellular_Location:
Membrane

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
GRM3

# Drug_Target_5_GenBank_ID_Gene:
X77748

# Drug_Target_5_GenBank_ID_Protein:
1171564

# Drug_Target_5_GeneCard_ID:
GRM3

# Drug_Target_5_Gene_Name:
GRM3

# Drug_Target_5_Gene_Sequence:
>2634 bp
ATGTTGACAAGACTGCAAGTTCTTACCTTAGCTTTGTTTTCAAAGGGATTTTTACTCTCT
TTAGGGGACCATAACTTTCTAAGGAGAGAGATTAAAATAGAAGGTGACCTTGTTTTAGGG
GGCCTGTTTCCTATTAACGAAAAAGGCACTGGAACTGAAGAATGTGGGCGAATCAATGAA
GACCGAGGGATTCAACGCCTGGAAGCCATGTTGTTTGCTATTGATGAAATCAACAAAGAT
GATTACTTGCTACCAGGAGTGAAGTTGGGTGTTCACATTTTGGATACATGTTCAAGGGAT
ACCTATGCATTGGAGCAATCACTGGAGTTTGTCAGGGCATCTTTGACAAAAGTGGATGAA
GCTGAGTATATGTGTCCTGATGGATCCTATGCCATTCAAGAAAACATCCCACTTCTCATT
GCAGGGGTCATTGGTGGCTCTTATAGCAGTGTTTCCATACAGGTGGCAAACCTGCTGCGG
CTCTTCCAGATCCCTCAGATCAGCTACGCATCCACCAGCGCCAAACTCAGTGATAAGTCG
CGCTATGATTACTTTGCCAGGACCGTGCCCCCCGACTTCTACCAGGCCAAAGCCATGGCT
GAGATCTTGCGCTTCTTCAACTGGACCTACGTGTCCACAGTAGCCTCCGAGGGTGATTAC
GGGGAGACAGGGATCGAGGCCTTCGAGCAGGAAGCCCGCCTGCGCAACATCTGCATCGCT
ACGGCGGAGAAGGTGGGCCGCTCCAACATCCGCAAGTCCTACGACAGCGTGATCCGAGAA
CTGTTGCAGAAGCCCAACGCGCGCGTCGTGGTCCTCTTCATGCGCAGCGACGACTCGCGG
GAGCTCATTGCAGCCGCCAGCCGCGCCAATGCCTCCTTCACCTGGGTGGCCAGCGACGGC
TGGGGCGCGCAGGAGAGCATCATCAAGGGCAGCGAGCATGTGGCCTACGGCGCCATCACC
CTGGAGCTGGCCTCCCAGCCTGTCCGCCAGTTCGACCGCTACTTCCAGAGCCTCAACCCC
TACAACAACCACCGCAACCCCTGGTTCCGGGACTTCTGGGAGCAAAAGTTTCAGTGCAGC
CTCCAGAACAAACGCAACCACAGGCGCGTCTGCGACAAGCACCTGGCCATCGACAGCAGC
AACTACGAGCAAGAGTCCAAGATCATGTTTGTGGTGAACGCGGTGTATGCCATGGCCCAC
GCTTTGCACAAAATGCAGCGCACCCTCTGTCCCAACACTACCAAGCTTTGTGATGCTATG
AAGATCCTGGATGGGAAGAAGTTGTACAAGGATTACTTGCTGAAAATCAACTTCACGGCT
CCATTCAACCCAAATAAAGATGCAGATAGCATAGTCAAGTTTGACACTTTTGGAGATGGA
ATGGGGCGATACAACGTGTTCAATTTCCAAAATGTAGGTGGAAAGTATTCCTACTTGAAA
GTTGGTCACTGGGCAGAAACCTTATCGCTAGATGTCAACTCTATCCACTGGTCCCGGAAC
TCAGTCCCCACTTCCCAGTGCAGCGACCCCTGTGCCCCCAATGAAATGAAGAATATGCAA
CCAGGGGATGTCTGCTGCTGGATTTGCATCCCCTGTGAACCCTACGAATACCTGGCTGAT
GAGTTTACCTGTATGGATTGTGGGTCTGGACAGTGGCCCACTGCAGACCTAACTGGATGC
TATGACCTTCCTGAGGACTACATCAGGTGGGAAGACGCCTGGGCCATTGGCCCAGTCACC
ATTGCCTGTCTGGGTTTTATGTGTACATGCATGGTTGTAACTGTTTTTATCAAGCACAAC
AACACACCCTTGGTCAAAGCATCGGGCCGAGAACTCTGCTACATCTTATTGTTTGGGGTT
GGCCTGTCATACTGCATGACATTCTTCTTCATTGCCAAGCCATCACCAGTCATCTGTGCA
TTGCGCCGACTCGGGCTGGGGAGTTCCTTCGCTATCTGTTACTCAGCCCTGCTGACCAAG
ACAAACTGCATTGCCCGCATCTTCGATGGGGTCAAGAATGGCGCTCAGAGGCCAAAATTC
ATCAGCCCCAGTTCTCAGGTTTTCATCTGCCTGGGTCTGATCCTGGTGCAAATTGTGATG
GTGTCTGTGTGGCTCATCCTGGAGGCCCCAGGCACCAGGAGGTATACCCTTGCAGAGAAG
CGGGAAACAGTCATCCTAAAATGCAATGTCAAAGATTCCAGCATGTTGATCTCTCTTACC
TACGATGTGATCCTGGTGATCTTATGCACTGTGTACGCCTTCAAAACGCGGAAGTGCCCA
GAAAATTTCAACGAAGCTAAGTTCATAGGTTTTACCATGTACACCACGTGCATCATCTGG
TTGGCCTTCCTCCCTATATTTTATGTGACATCAAGTGACTACAGAGTGCAGACGACAACC
ATGTGCATCTCTGTCAGCCTGAGTGGCTTTGTGGTCTTGGGCTGTTTGTTTGCACCCAAG
GTTCACATCATCCTGTTTCAACCCCAGAAGAATGTTGTCACACACAGACTGCACCTCAAC
AGGTTCAGTGTCAGTGGAACTGGGACCACATACTCTCAGTCCTCTGCAAGCACGTATGTG
CCAACGGTGTGCAATGGGCGGGAAGTCCTCGACTCCACCACCTCATCTCTGTGA

# Drug_Target_5_General_Function:
Amino acid transport and metabolism

# Drug_Target_5_General_References:
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
8840013	Makoff A, Volpe F, Lelchuk R, Harrington K, Emson P: Molecular characterization and localization of human metabotropic glutamate receptor type 3. Brain Res Mol Brain Res. 1996 Aug;40(1):55-63.

# Drug_Target_5_HGNC_ID:
HGNC:4595

# Drug_Target_5_HPRD_ID:
Not Available

# Drug_Target_5_ID:
4096

# Drug_Target_5_Locus:
7q21.1-q21.2

# Drug_Target_5_Molecular_Weight:
98880

# Drug_Target_5_Name:
Metabotropic glutamate receptor 3

# Drug_Target_5_Number_of_Residues:
879

# Drug_Target_5_PDB_ID:
Not Available

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00003	7tm_3
PF01094	ANF_receptor
PF07562	NCD3G

# Drug_Target_5_Protein_Sequence:
>Metabotropic glutamate receptor 3
MKMLTRLQVLTLALFSKGFLLSLGDHNFLRREIKIEGDLVLGGLFPINEKGTGTEECGRI
NEDRGIQRLEAMLFAIDEINKDDYLLPGVKLGVHILDTCSRDTYALEQSLEFVRASLTKV
DEAEYMCPDGSYAIQENIPLLIAGVIGGSYSSVSIQVANLLRLFQIPQISYASTSAKLSD
KSRYDYFARTVPPDFYQAKAMAEILRFFNWTYVSTVASEGDYGETGIEAFEQEARLRNIC
IATAEKVGRSNIRKSYDSVIRELLQKPNARVVVLFMRSDDSRELIAAASRANASFTWVAS
DGWGAQESIIKGSEHVAYGAITLELASQPVRQFDRYFQSLNPYNNHRNPWFRDFWEQKFQ
CSLQNKRNHRRVCDKHLAIDSSNYEQESKIMFVVNAVYAMAHALHKMQRTLCPNTTKLCD
AMKILDGKKLYKDYLLKINFTAPFNPNKDADSIVKFDTFGDGMGRYNVFNFQNVGGKYSY
LKVGHWAETLSLDVNSIHWSRNSVPTSQCSDPCAPNEMKNMQPGDVCCWICIPCEPYEYL
ADEFTCMDCGSGQWPTADLTGCYDLPEDYIRWEDAWAIGPVTIACLGFMCTCMVVTVFIK
HNNTPLVKASGRELCYILLFGVGLSYCMTFFFIAKPSPVICALRRLGLGSSFAICYSALL
TKTNCIARIFDGVKNGAQRPKFISPSSQVFICLGLILVQIVMVSVWLILEAPGTRRYTLA
EKRETVILKCNVKDSSMLISLTYDVILVILCTVYAFKTRKCPENFNEAKFIGFTMYTTCI
IWLAFLPIFYVTSSDYRVQTTTMCISVSLSGFVVLGCLFAPKVHIILFQPQKNVVTHRLH
LNRFSVSGTGTTYSQSSASTYVPTVCNGREVLDSTTSSL

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
1-22

# Drug_Target_5_Specific_Function:
Receptor for glutamate. The activity of this receptor is mediated by a G-protein that inhibits adenylate cyclase activity

# Drug_Target_5_SwissProt_ID:
Q14832

# Drug_Target_5_SwissProt_Name:
GRM3_HUMAN

# Drug_Target_5_Synonyms:
Metabotropic glutamate receptor 3 precursor
mGluR3

# Drug_Target_5_Theoretical_pI:
7.70

# Drug_Target_5_Transmembrane_Regions:
577-599
614-634
646-664
689-709
735-756
770-792
803-828

#END_DRUGCARD DB00659
